Comparison
Citicoline vs NMN
Side-by-side of Citicoline and NMN. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Citicoline
Citicoline supplement profile: CDP-choline as a phosphatidylcholine precursor, Cognizin dosing 250-2000 mg, cognition trials, stroke recovery evidence.
NMN
NMN supplements are oral nicotinamide mononucleotide capsules sold for longevity, energy, and metabolic health. They raise plasma NAD+ 30-90% at 250-1000.
Effects at a glance
Citicoline
- •Choline donor and phosphatidylcholine precursor; oral bioavailability roughly 99%
- •Standard prescription medication for stroke recovery and vascular cognitive impairment in much of the world
- •Healthy-adult cognitive trials (Cognizin) report small gains in attention and working memory at 250 to 500 mg/day
- •ICTUS trial (n=2,298) was negative on stroke recovery in the modern thrombolysis era
- •Lower per-gram choline content than alpha-GPC (~18% vs ~40%), meaning smaller TMAO load at equivalent dose
- •Long uridine half-life (~56 hours) supports once or twice daily dosing
NMN
- •Plasma NAD+ rises 30-90% at 250-1000 mg/day across human PK studies
- •Tissue NAD+ rise is inconsistent across human trials (Yoshino 2021, Igarashi 2022)
- •No human trials measure hard endpoints (mortality, CV events, cancer); evidence is biomarker-only
- •Most trials cluster at 250-500 mg/day; dose-response above 250 mg/day is poorly characterized
- •FDA position contested; widely sold as supplement but with regulatory uncertainty
- •Marketing claims for fertility and longevity outrun the human trial evidence substantially
Side-by-side
| Attribute | Citicoline | NMN |
|---|---|---|
| Category | supplement | supplement |
| Also known as | CDP-choline, cytidine 5'-diphosphocholine, Cognizin | nicotinamide mononucleotide, beta-NMN |
| Half-life (hr) ↗ | 56 | 4 |
| Typical dose (mg) ↗ | 500 | 250 |
| Dosing frequency | 1 to 2 times daily | 1x daily, often morning |
| Routes | oral, intravenous | oral, sublingual |
| Onset (hr) | 1 | 1 |
| Peak (hr) | 2 | 3 |
| Molecular weight | 488.32 | 334.22 |
| Molecular formula | C14H26N4O11P2 | C11H15N2O8P |
| Mechanism | Hydrolyzed to cytidine and choline after absorption; both cross the blood-brain barrier and are recombined intracellularly to reform CDP-choline, supporting phosphatidylcholine synthesis and acetylcholine production. | Direct precursor in the NAD+ salvage pathway; converted to NAD+ by NMNAT enzymes in essentially every tissue. Raised NAD+ supports sirtuin and PARP enzyme activity. |
| Legal status | Dietary supplement (US, Cognizin GRAS); prescription medication in most of the world | Contested in US (FDA position 2022); widely sold as supplement; broadly available in EU, UK, Asia |
| WADA status | allowed | allowed |
| DEA / Rx | OTC supplement (US); Rx in most of the world | Not scheduled |
| Pregnancy | Insufficient data for routine use | Insufficient data; precautionary avoidance |
| CAS | 987-78-0 | 1094-61-7 |
| PubChem CID | 13804 | 14180 |
| Wikidata | Q411470 | Q418972 |
Safety profile
Citicoline
Common side effects
- mild GI upset
- headache
- restlessness
- occasional insomnia with evening dosing
Contraindications
- concurrent strong anticholinergic therapy
- established cardiovascular disease (TMAO concern, smaller than alpha-GPC)
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors: additive cholinergic effect(minor)
- antimetabolite chemotherapy (5-FU): theoretical cytidine pathway interaction(minor)
NMN
Common side effects
- mild GI upset (rare)
- occasional headache
- flushing (rare)
Contraindications
- pregnancy and lactation (precautionary, no data)
- active cancer (theoretical concern, not evidence-based)
Interactions
- metformin: no clinically significant interaction documented; both modulate metabolism through different mechanisms(minor)
- chemotherapy agents: theoretical concern about supporting cancer cell proliferation; coordinate with oncology team(moderate)
- CD38 inhibitors: would amplify NMN-induced NAD+ rise; not clinically relevant for most users(minor)
Which Should You Take?
Citicoline comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. NMN is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Citicoline.
- → If your priority is stroke recovery, pick Citicoline.
- → If your priority is healthspan extension, pick NMN.
- → If your priority is energy and stamina, pick NMN.
Edge case: If you want to avoid Contested in US (FDA position 2022); widely sold as supplement; broadly available in EU, UK, Asia, Citicoline is the more accessible choice.
Default choice: Citicoline. Lower friction to source, and broader goal coverage. Reach for NMN only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Citicoline and NMN?
Citicoline and NMN differ in category (supplement vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Citicoline or NMN?
Citicoline half-life is 56 hours; NMN half-life is 4 hours.
Can you stack Citicoline with NMN?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper